ENTRADA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ENTRADA THERAPEUTICS, INC. (TRDA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-26
- ENTRADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -1.70%, a 160.71% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 2.80%, a 74.55% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 11.00%.
- ENTRADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -1.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -1.70% 10-K · filed 2026-02-26 | |
| 2024-12-31 | 2.80% 10-K · filed 2026-02-26 | 3.00% 10-K · filed 2025-02-27 |
| 2023-12-31 | 11.00% 10-K · filed 2025-02-27 | 11.30% 10-K · filed 2024-03-13 |
| 2022-12-31 | -1.40% 10-K · filed 2024-03-13 | |
| 2021-12-31 | -0.30% 10-K · filed 2023-03-06 | |
| 2020-12-31 | -0.20% 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |